Shire plc Shire Plc : Director Declaration

Features Dow Jones Newswires

TIDMSHP TIDMSHP

Continue Reading Below

Director Declaration

December 19, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company")

announces that Bill Burns, Senior Independent Director of the Company,

was appointed Vice-Chairman and Director of Molecular Partners on

October 31, 2017.

Continue Reading Below

This disclosure is made pursuant to LR 9.6.14 of the UK Listing Rules.

Oliver Strawbridge

Senior Assistant Company Secretary

For further information please contact:

Investor Relations

Ian Karp ikarp@shire.com +1 781 482 9018

Robert Coates rcoates@shire.com +44 203 549 0874

Media

Lisa Adler lisa.adler@shire.com +1 617 588 8607

Katie Joyce kjoyce@shire.com +1 781 482 2779

NOTES TO EDITORS

About Shire

Shire is the global leader in serving patients with rare diseases. We

strive to develop best-in-class therapies across a core of rare disease

areas including hematology, immunology, genetic diseases, neuroscience,

and internal medicine with growing therapeutic areas in ophthalmics and

oncology. Our diversified capabilities enable us to reach patients in

more than 100 countries who are struggling to live their lives to the

fullest.

We feel a strong sense of urgency to address unmet medical needs and

work tirelessly to improve people's lives with medicines that have a

meaningful impact on patients and all who support them on their journey.

www.shire.com

This announcement is distributed by Nasdaq Corporate Solutions on behalf

of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Shire plc via Globenewswire

(END) Dow Jones Newswires

December 19, 2017 07:15 ET (12:15 GMT)